for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Recordati SpA

RECI.MI

Latest Trade

40.63EUR

Change

-0.37(-0.90%)

Volume

529,909

Today's Range

40.38

 - 

41.12

52 Week Range

32.50

 - 

42.22

As of on the Italian SE (Mercato Continuo Italia) ∙ Minimum 15 minute delay

Pricing

Previous Close
41.00
Open
40.98
Volume
529,909
3M AVG Volume
6.88
Today's High
41.12
Today's Low
40.38
52 Week High
42.22
52 Week Low
32.50
Shares Out (MIL)
205.66
Market Cap (MIL)
8,496.76
Forward P/E
--
Dividend (Yield %)
2.34

Next Event

Recordati Industria Chimica e Farmaceutica SpA Annual Shareholders Meeting

Latest Developments

More

Recordati Prelim. FY EBITDA At EUR 544 Mln, Up 9.0% Yr/Yr

Recordati Says European Commission Approves Market Placing Of Isturisa Drug

Recordati Q3 Net Profit Up At EUR 79.4 Mln

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Recordati SpA

Recordati Industria Chimica e Farmaceutica SpA is an Italy-based group engaged in the research, development, manufacture and marketing of pharmaceuticals. It promotes a wide range of pharmaceuticals, both proprietary and under license, in a number of therapeutic areas, such as Antibiotics and Antiviral, Cardiovascular, Central nervous system, Dermatological, Gastroenterology, Genital-urinary system, Muscular-skeletal disorders and pain therapy, Obstetrics and Gynecology and over the counter (OTC) pharmaceuticals. The Company is engaged in the research and development of new drug entities within the cardiovascular and urogenital therapeutic areas and of treatments for rare diseases. It’s product is ZANIDIP, a latest generation calcium-channel blocker for the treatment hypertension. It operates through Italchimici SpA, Pro Farma AG and North American marketing rights to Cystadane. The Company owns and operates through Natural Point srl also in the food supplement sector.

Contact Info

Via M. Civitali, 1

+39.02.487871

http://www.recordati.com

Executive Leadership

Flemming Ornskov

Chairman of the Board

Andrea Recordati

Chief Executive Officer, Executive Director

Alfredo Altavilla

Vice Chairman of the Board

Fritz Squindo

Chief Financial Officer, Financial Reporting Officer, Managing Director, Executive Director

Corrado Castellucci

Executive Vice President - Rare Diseases Business Unit

Key Stats

2.56 mean rating - 9 analysts
Sell
Hold
Buy
Revenue (MM, EUR)

2017

1.3K

2018

1.4K

2020(E)

1.6K
EPS (EUR)

2017

1.381

2018

1.494

2020(E)

1.746
Price To Earnings (TTM)
25.88
Price To Sales (TTM)
5.90
Price To Book (MRQ)
7.08
Price To Cash Flow (TTM)
21.34
Total Debt To Equity (MRQ)
95.24
LT Debt To Equity (MRQ)
85.27
Return on Investment (TTM)
16.97
Return on Equity (TTM)
13.84

Latest News

Latest News

BRIEF-Recordati FY Prelim. Net Profit Up 21.6 Pct At EUR 288.8 Mln

* FY PRELIM NET REVENUES EUR 1,288.1 MILLION, UP 11.6 PERCENT YEAR ON YEAR

BRIEF-Recordati Q3 net profit up at EUR 72.8 mln, confirms FY targets

* Q3 NET PROFIT EUR 72.8 MILLION VERSUS EUR 59.6 MILLION YEAR AGO

BRIEF-Recordati: European Commission approves Reagila as schizophrenia treatment

* EUROPEAN COMMISSION APPROVES REAGILA (CARIPRAZINE) FOR TREATMENT OF SCHIZOPHRENIA Source text: http://bit.ly/2teBSwQ Further company coverage: (Gdynia Newsroom)

BRIEF-Recordati signs exclusive license agreement with MimeTech

RECORDATI INDUSTRIA CHIMICA E FARMACEUTICA SPA:

AstraZeneca sells aging beta-blocker to Recordati for $300 million

AstraZeneca <AZN.L> has sold the European rights to its aging beta-blocker heart drug Seloken to Italy's Recordati <RECI.MI> for $300 million, as part of a continuing drive by the British drugmaker to spin off non-core assets.

BRIEF-Italy's Recordati sees 2019 sales at around 1.45 bln euros

* sees 2019 sales at around 1.45 billion euros Source text for Eikon: Further company coverage: (Reporting by Milan newsroom)

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up